Loading clinical trials...
Loading clinical trials...
Arsenic Trioxide Therapy for Interferon Alpha Refractory or Intolerant Chronic Phase Chronic Myelogenous Leukemia
Conditions
Interventions
arsenic trioxide
Start Date
June 19, 2000
Primary Completion Date
January 1, 2002
Completion Date
January 1, 2002
Last Updated
November 14, 2018
NCT07388563
NCT00106925
NCT06311227
NCT06285890
NCT06852222
NCT06220162
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions